Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Company Performance - Xeris Biopharma's shares have increased by 32.4% over the past month, reaching a new 52-week high of $7.61 [1] - The stock has gained 112.4% since the beginning of the year, outperforming the Zacks Medical sector, which declined by 7.5%, and the Zacks Medical - Drugs industry, which returned 5.3% [1] Earnings and Revenue Expectations - Xeris Biopharma has consistently beaten earnings estimates, with the latest EPS reported at -$0.01 against a consensus estimate of -$0.03 [2] - For the current fiscal year, the company is expected to post earnings of -$0.05 per share on revenues of $285.65 million, reflecting an 84.85% change in EPS and a 40.67% change in revenues [3] - For the next fiscal year, earnings are projected to be $0.20 per share on revenues of $346.4 million, indicating a year-over-year change of 485% in EPS and 21.27% in revenues [3] Valuation Metrics - Xeris Biopharma currently has a Value Score of D, while its Growth and Momentum Scores are both A, resulting in a combined VGM Score of A [6] - The stock holds a Zacks Rank of 2 (Buy) due to rising earnings estimates, suggesting potential for further growth [7][8] Industry Comparison - The Medical - Drugs industry is positioned in the top 35% of all industries, indicating favorable conditions for both Xeris Biopharma and its peer, Rigel Pharmaceuticals [11] - Rigel Pharmaceuticals has a Zacks Rank of 1 (Strong Buy) and has shown strong earnings performance, beating consensus estimates by 66.50% [9][10]